Recursion (RXRX) Q2 Revenue Jumps 33%
Recursion Pharmaceuticals (NASDAQ:RXRX), a technology-driven biotech company decoding biology using artificial intelligence for drug discovery, released its financial results for the second quarter of 2025 on August 5, 2025. The headline was a notable revenue beat, with GAAP revenue reaching $19.2 million against analyst expectations of $15.37 million, helped by collaboration milestones. However, research and development expenses surged, leading to a larger net loss of $171.9 million (GAAP). Earnings per share (EPS, GAAP) came in at ($0.41), slightly worse than the prior-year period and matching the ($0.35) consensus. Cash reserves were $533.8 million. Overall, the period showcased advances in revenue generation and technology partnerships, but also underscored elevated spending and the ongoing challenge of moving early-stage drug programs toward commercialization.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Recursion Pharmaceuticals is known for its Recursion Operating System (Recursion OS), a full-stack platform that uses artificial intelligence (AI), automation, and massive biological datasets to accelerate drug discovery. The company focuses on integrating advanced data analytics and technology to identify and develop new medicine candidates more efficiently.
Source Fool.com
